Story perspectives

PanCAN Advances Pancreatic Cancer Research and Support in 2025

12/21/2025

Summary

Story summary

In 2025, the Pancreatic Cancer Action Network (PanCAN) advanced research and patient support.
PanCAN launched a partnership with Smart Patients to connect patients and caregivers.
PanCAN introduced Research Recovery Grants to safeguard promising projects amid funding uncertainties.
The RASOLUTE 302 trial tested daraxonrasib as a treatment targeting RAS mutations in pancreatic cancer.
The Early Detection Initiative enrolled over 8,800 participants to study blood sugar changes and imaging.

1 of 1

Story summary

In 2025, the Pancreatic Cancer Action Network (PanCAN) advanced research and patient support.
PanCAN launched a partnership with Smart Patients to connect patients and caregivers.
PanCAN introduced Research Recovery Grants to safeguard promising projects amid funding uncertainties.
The RASOLUTE 302 trial tested daraxonrasib as a treatment targeting RAS mutations in pancreatic cancer.
The Early Detection Initiative enrolled over 8,800 participants to study blood sugar changes and imaging.